Purpose

This section provides a high-level summary of the ANCOVA treatment efficacy comparison analysis configuration, including the dataset characteristics, column mappings, and analysis parameters.

Key Findings

• Analysis Type: Analysis of Covariance (ANCOVA) with Type III sum of squares
• Covariates Controlled: Baseline severity and age
• Outcome: Primary continuous endpoint compared across treatment groups

Interpretation

The overview card documents the analysis setup and confirms the data was properly loaded and mapped. Review the column mapping to verify semantic names correspond to the correct columns in your dataset.

Context

Valid ANCOVA requires a continuous outcome, a categorical treatment factor, and continuous covariates with linear relationships to the outcome.

Purpose

This section summarizes the data cleaning and preprocessing steps performed before ANCOVA, including row removal due to missing values and group composition.

Key Findings

• Listwise Deletion: Rows with missing values in required columns removed
• Type Conversion: Treatment group converted to factor; outcome and covariates converted to numeric
• Group Validation: Minimum 2 groups required for ANCOVA

Interpretation

Listwise deletion ensures only complete cases enter the ANCOVA model. High retention rates (few rows removed) indicate good data quality. Review group counts to ensure adequate sample per treatment arm for reliable ANCOVA estimates.

Context

ANCOVA requires minimum 30 total observations and ideally 10+ per group after preprocessing for stable covariate adjustment.

Purpose

This executive summary consolidates the most critical ANCOVA findings into a decision-ready format: treatment effect significance, effect size, pairwise comparison results, and model fit.

Key Findings

• Treatment Effect: F-statistic, p-value, and significance determination from Type III ANCOVA
• Effect Size: Partial eta-squared with Cohen benchmark interpretation (small/medium/large)
• Pairwise Comparisons: Number of significant Tukey-corrected group differences

Interpretation

The key findings table provides the complete ANCOVA result summary suitable for clinical reporting. Significant F-test with non-trivial partial eta-squared indicates genuine treatment differences beyond baseline covariate effects.

Context

Results are valid when ANCOVA assumptions hold. Review the assumption diagnostics slide for slope homogeneity, normality, and variance equality checks before drawing causal conclusions.

Headline

None of the three treatment groups showed a meaningful difference in outcomes after adjusting for age and blood pressure (F=0.27, p=0.765).

Purpose

This ANCOVA section tests whether Drug A, Drug B, and Placebo produce different results on the primary outcome, while statistically removing the influence of two patient characteristics (age and diastolic blood pressure) that could confound the comparison. This is the core hypothesis test for the trial—it answers whether the treatments actually work differently from each other.

Key Findings

• F-statistic: 0.27 with p-value of 0.765 — far above the 0.05 significance threshold, indicating no detectable treatment effect
• Partial eta-squared: 0.000 — the treatment groups explain zero percent of outcome variance after covariate adjustment
• Model R-squared: 0.002 — even with covariates included, the entire model explains only 0.2% of outcome variation
• Sample size: 1,000 patients across three groups provides strong statistical power to detect real differences, yet none emerged

Interpretation

The analysis found no evidence that Drug A, Drug B, or Placebo differ meaningfully in their effect on the outcome. The p-value of 0.765 means there is a 76.5% probability of observing this data (or more extreme) if all three treatments truly had identical effects. The negligible effect size confirms this is not a case of a real but small difference being missed due to sample size—the groups genuinely performed similarly. Adjusting for age and baseline blood pressure did not reveal hidden treatment effects.

Context

With 1,000 patients, the study had excellent power to detect even modest treatment differences. The failure to find significance is not due to insufficient sample size. However, the extremely low model R² (0.2%) suggests substantial unexplained outcome variation, indicating either high individual variability in response or unmeasured confounding factors.

Headline

All three treatment groups produce nearly identical outcomes (range 0.88 points), with confidence intervals that overlap completely—no meaningful difference exists between Drug A, Drug B, and Placebo.

Purpose

Adjusted marginal means isolate the effect of each treatment by holding covariates (Age and Diastolic BP) constant at their average values. This section answers whether the three treatment groups differ in their expected outcome after accounting for baseline differences. Overlapping confidence intervals are the visual signal that differences are not statistically or practically meaningful.

Key Findings

• Drug A adjusted mean: 120.07 (95% CI: 118.31–121.84)
• Drug B adjusted mean: 119.2 (95% CI: 117.47–120.92)
• Placebo adjusted mean: 119.4 (95% CI: 117.77–121.03)
• Mean range across groups: 0.88 points—the largest difference (Drug A vs. Drug B) is less than 1 unit
• Confidence interval overlap: All three intervals span roughly 117.5–121.8, with substantial overlap

Interpretation

The adjusted means are nearly identical across all three groups. Drug A's highest mean of 120.07 exceeds Drug B's lowest mean of 119.2 by less than 1 point—a trivial difference. The wide, overlapping confidence intervals confirm that this small numerical difference could easily be due to random variation. After adjusting for age and baseline diastolic BP, the treatment groups show no meaningful separation in outcomes.

Context

This finding aligns with the earlier ANCOVA result (F=0.27, p=0.765), which showed no significant treatment effect. The confidence intervals here provide the practical picture: even the best-case scenario for any drug shows overlap with placebo, indicating no clinically or statistically meaningful advantage.

Headline

None of the three treatment comparisons showed statistically significant differences — all adjusted p-values exceeded 0.76, meaning Drug A, Drug B, and Placebo produced equivalent outcomes.

Purpose

This section tests whether any pair of treatments differs meaningfully from the others. Pairwise comparisons are the follow-up to the overall ANCOVA test; they pinpoint which specific groups diverge. Tukey HSD adjustment controls for multiple testing, so a p-value above 0.05 here is a genuine null result, not a false negative from repeated comparisons.

Key Findings

• Drug A vs. Drug B: Difference of +0.88 units (95% CI: −1.58 to +3.34, p=0.76) — not significant
• Drug A vs. Placebo: Difference of +0.67 units (95% CI: −1.73 to +3.07, p=0.85) — not significant
• Drug B vs. Placebo: Difference of −0.21 units (95% CI: −2.58 to +2.16, p=0.98) — not significant
• Confidence Intervals: All three cross zero, confirming no meaningful separation between groups

Interpretation

The confidence intervals are wide relative to the point estimates, reflecting substantial uncertainty around each comparison. Even the largest observed difference (Drug A vs. Drug B at 0.88 units) could plausibly be zero or even reversed in the opposite direction. This aligns with the overall ANCOVA result (F=0.27, p=0.765), which found no treatment effect. The data provide no evidence that either active drug outperforms placebo or each other.

Context

These results assume the ANCOVA model is correctly specified and assumptions are reasonably met. The normality assumption was violated (Shapiro-Wilk p<0.001), which may inflate uncertainty; however, with n=1,000, the Central Limit Theorem provides robustness. The wide confidence intervals suggest the study may be underpowered to detect small clinically meaningful differences.

Headline

The relationship between baseline severity and outcome is statistically identical across all three treatment groups (p = 0.67), confirming that ANCOVA adjustment is valid.

Purpose

This section tests a critical assumption underlying ANCOVA: that the covariate (baseline severity) affects the outcome in the same way regardless of which treatment group a patient receives. If this assumption holds, the three treatment groups have parallel regression lines, and we can fairly adjust outcome differences for baseline differences. If slopes diverge significantly, the treatment effect would depend on baseline severity, invalidating the ANCOVA model.

Key Findings

• Slope Homogeneity p-value: 0.67 — far above the 0.05 significance threshold, indicating no evidence of group-by-covariate interaction
• Assumption Status: PASSED — parallel slopes confirmed across Drug A, Drug B, and Placebo groups
• Baseline Severity Range: 47–120 (mean 80.2, SD 10.6) with symmetric distribution (skew 0.05)
• Outcome Range: 73–200 (mean 119.5, SD 15.8) with minimal skew (0.1)

Interpretation

The high p-value (0.67) provides strong evidence that baseline severity influences outcome identically in all three groups. This means the treatment effect is not conditional on how sick patients were at baseline — a patient with low baseline severity responds to each drug similarly to how a high-baseline patient responds. This validates the ANCOVA model's core assumption and supports the adjusted mean comparisons reported elsewhere in the analysis.

Context

With 1,000 observations balanced across three groups (311–363 per group), the test has adequate power to detect meaningful slope differences. The parallel slopes assumption is essential for interpreting the treatment group differences as unconfounded by baseline severity.

Purpose

The QQ plot visually assesses whether ANCOVA model residuals follow a normal distribution, which is a key assumption for valid F-tests and confidence intervals.

Key Findings

• Diagonal Alignment: Points close to the reference line confirm normality
• Shapiro-Wilk Test: p-value > 0.05 indicates normally distributed residuals
• Tail Behavior: Systematic deviations in tails suggest heavy-tailed or skewed residuals

Interpretation

When points in the QQ plot align closely with the diagonal red reference line, residuals are approximately normally distributed and the ANCOVA assumption is satisfied. Deviation patterns (S-curves, heavy tails) suggest potential issues but ANCOVA is robust with larger samples.

Context

With n > 30 per group, ANCOVA is fairly robust to mild normality violations due to the Central Limit Theorem. Severe violations warrant non-parametric alternatives like Kruskal-Wallis.

Purpose

This table summarizes all three formal ANCOVA assumption tests in one place: slope homogeneity, normality of residuals, and homogeneity of variance.

Key Findings

• Slope Homogeneity: Non-significant interaction F-test (p > 0.05) confirms parallel regression slopes
• Normality: Shapiro-Wilk p > 0.05 confirms approximately normal residuals
• Levene Test: Non-significant Levene test (p > 0.05) confirms equal variance across groups

Interpretation

All three passing (PASS) indicates the ANCOVA model is appropriate and results are trustworthy. Failed assumptions do not necessarily invalidate results — ANCOVA is robust to mild violations — but they warrant caution in interpretation and reporting.

Context

The number of outliers (studentized residuals |r| > 3) is also reported. Influential outliers can disproportionately affect covariate adjustment slopes and adjusted means.